TLV has prepared a health economic assessment for Swedish regions on Blenrep (belantamab mafodotin) used with bortezomib + dexamethasone (BVd) in adults with multiple myeloma who have received at least one prior therapy.
Clinical basis
A phase III study directly compared BVd vs DVd (daratumumab, bortezomib and dexametasone) and showed longer time with disease control and longer overall survival for patients treated with BVd. TLV considers it reasonable to assume the effect advantage also applies versus TLV’s chosen relevant comparator.
Comparator used by TLV
TLV changed the comparator from DVd to a basket of comparators based on learnings from previous assessment of Carvukti. The treatment basket consisting of:
-
30% DPd (darzalex, pomalidomide and dexametasone) , 40 % PVd (pomalidomide, bortezomib and dexametasone), 30% Kd (carfilzomib and dexametasone)
Cost-effectiveness results
-
Cost per gained QALY: ~SEK 3.9 million
-
Sensitivity analyses: ~SEK 3.3–4.9 million per QALY
The assessment is handed to the NT council to support their decision to the regions.
